DNTH (STOCKS)
Dianthus Therapeutics, Inc. Common Stock
$82.510000
+0.440000 (+0.54%)
Prev close: $82.070000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Marino Garcia
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,513.79M
- Employees
- 78
- P/E (TTM)
- -19.94
- P/B (TTM)
- 3.73
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
10
Strong Buy
11
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.85 | $-1.09 | +0.2436 | +22.28% |
|
Dec 2025 (Q4)
|
$-1.43 | $-1.10 | -0.3328 | -30.33% |
|
Sep 2025 (Q3)
|
$-0.97 | $-0.88 | -0.0904 | -10.28% |
|
Jun 2025 (Q2)
|
$-0.88 | $-0.89 | +0.0091 | +1.02% |
Financial Statements
| Revenues | $1.34M |
| Benefits Costs and Expenses | $106.01M |
| Costs And Expenses | $187.52M |
| Nonoperating Income/Loss | $17.63M |
| Operating Expenses | $192.63M |
| Research and Development | $153.16M |
| Other Operating Expenses | $39.46M |
| Operating Income/Loss | -$191.29M |
| Income/Loss From Continuing Operations After Tax | -$173.66M |
| Income/Loss From Continuing Operations Before Tax | -$136.50M |
| Net Income/Loss | -$173.66M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$173.66M |
| Net Income/Loss Available To Common Stockholders, Basic | -$173.66M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.22 |
| Diluted Earnings Per Share | -$4.22 |
| Basic Average Shares | 123,790,348 |
| Diluted Average Shares | 123,790,348 |
| Assets | $1.25B |
| Current Assets | $1.12B |
| Cash | $617.11M |
| Other Current Assets | $502.80M |
| Noncurrent Assets | $126.97M |
| Fixed Assets | $274.00K |
| Other Non-current Assets | $126.70M |
| Liabilities | $45.57M |
| Current Liabilities | $38.28M |
| Accounts Payable | $5.27M |
| Wages | $2.70M |
| Other Current Liabilities | $30.31M |
| Noncurrent Liabilities | $7.29M |
| Equity | $1.20B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.20B |
| Liabilities And Equity | $1.25B |
| Net Cash Flow From Operating Activities | -$130.29M |
| Net Cash Flow From Operating Activities, Continuing | -$130.29M |
| Net Cash Flow From Investing Activities | -$271.60M |
| Net Cash Flow From Investing Activities, Continuing | -$271.60M |
| Net Cash Flow From Financing Activities | $1.02B |
| Net Cash Flow From Financing Activities, Continuing | $1.02B |
| Net Cash Flow | $617.49M |
| Net Cash Flow, Continuing | $617.49M |
| Comprehensive Income/Loss | -$174.33M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$174.51M |
| Other Comprehensive Income/Loss | -$37.44M |
| Other Comprehensive Income/Loss Attributable To Parent | -$845.00K |